Grant-to-equity project support — historical disclosure · Biotech
Sikerui describes grant-to-equity backing for TIL development
The Taizhou biotechnology company says public financial support helped establish its cell-therapy development operations.
Sikerui (Taizhou) Biotechnology founder Zhu Wenjun described grant-to-equity financial support for the company in an April 27, 2026 report. The backing helped the business establish its development operations; the report did not disclose an individual funding amount.
The company is developing third-generation tumour-infiltrating lymphocyte therapies, combining research in Shanghai with laboratory work in Taizhou. The same report describes local assistance with obtaining the materials needed for cell culture as its validation work advances.
Use of funds
Support development of third-generation tumour-infiltrating lymphocyte therapies.
Funding history
Grant-to-equity project support — historical disclosure · This roundUndisclosed